Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer (FOSCO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00889343 |
|
Recruitment Status :
Terminated
First Posted : April 28, 2009
Last Update Posted : March 4, 2013
|
Sponsor:
AIO-Studien-gGmbH
Information provided by (Responsible Party):
AIO-Studien-gGmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine whether sorafenib in combination with chemotherapy has a positive effect on time to progression of the tumor or death for the treatment of large bowel cancer that has already progressed during a first chemotherapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Neoplasms | Drug: Sorafenib Drug: Placebo Drug: Oxaliplatin or Irinotecan Drug: Leucovorin Drug: 5-Fluorouracil | Phase 2 |
Patients with metastatic CRC who received a first-line therapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab and had a progression subsequently, are eligible for this study. Patients will be randomized to receive chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib 400 mg bid or chemotherapy + placebo. Patients who have received an Oxaliplatin based Fluoropyrimidine containing regimen in first-line will obtain FOLFIRI during this study. Patients who have received an Irinotecan based Fluoropyrimidine containing regimen in first-line will obtain FOLFOX6.
Primary objective of the study is to compare the Progression-free-survival (PFS) between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 101 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma |
| Study Start Date : | March 2009 |
| Actual Primary Completion Date : | November 2011 |
| Actual Study Completion Date : | December 2012 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Colorectal Cancer
| Arm | Intervention/treatment |
|---|---|
| Experimental: 1 |
Drug: Sorafenib
2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
Other Name: Nexavar Drug: Oxaliplatin or Irinotecan Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle Drug: Leucovorin 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle Drug: 5-Fluorouracil 400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle |
| Placebo Comparator: 2 |
Drug: Placebo
2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral Drug: Oxaliplatin or Irinotecan Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle Drug: Leucovorin 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle Drug: 5-Fluorouracil 400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle |
Primary Outcome Measures :
- To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo [ Time Frame: 6 to 12 months ]
Secondary Outcome Measures :
- Disease control rate [ Time Frame: 6 to 12 months ]
- Overall survival [ Time Frame: 6 to 12 months ]
- Response rates [ Time Frame: 6 to 12 months ]
- Safety [ Time Frame: signature of informed consent until 30 days after end of treatment ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age > 18 years.
- ECOG Performance Status of 0 to 2
- Life expectancy of at least 12 weeks.
- Subjects with at least one uni-dimensional (RECIST) measurable lesion of metastatic colorectal carcinoma after first-line chemotherapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab and had a progression subsequently. Lesions must be measured by CT-scan or MRI.
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- Hemoglobin > 9.0 g/dl
- Absolute neutrophil count (ANC) >1,500/mm3
- Platelet count 100,000/μl Total bilirubin < 1.5 times the upper limit of normal
- ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer)
- Alkaline phosphatase < 4 x upper limit of normal
- PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]
- Serum creatinine < 1.5 x upper limit of normal
- Signed and dated informed consent before the start of specific protocol procedures
Exclusion Criteria:
- History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension
- History of HIV infection or chronic hepatitis B or C
- Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
- Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- History of organ allograft
- Patients with evidence or history of bleeding diathesis
- Patients undergoing renal dialysis
- Known deficit in Dihydropyrimidine Deshydrogenase (DPD)
- Contraindications for the use of atropine in patients receiving FOLFIRI
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- Peripheral sensory neuropathy > CTC grade 2
- Chronic inflammatory bowel disease; ileus; genetic fructose intolerance
- Pregnant or breast-feeding patients.
- Women of childbearing potential must have a negative pregnancy test performed within 7 days before the start of treatment. Fertile women and men (<2 years after last menstruation in women) must use effective means of contraception (intrauterine contraceptive device, contraceptive implants, injectables (hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual abstinence or vasectomised partner) during treatment and for at least 6 months after last administration of medication.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient‟s participation in the study or evaluation of the study results
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study 18. Patients unable to swallow oral medications.
- Any other anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry.
- Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed). Major surgery within 4 weeks of start of study
- Autologous bone marrow transplant or stem cell rescue within 4 months prior to study treatment
- Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however, they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study]
- Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- Prior exposure to the study drug.
- Any St. John´s wort containing remedy
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00889343
Hide Study Locations
Locations
| Germany | |
| Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum | |
| Pforzheim, Baden-Würtemberg, Germany, 75179 | |
| Ostalb-Klinikum Aalen, Medizinische Klinik 1 | |
| Aalen, Baden-Württemberg, Germany, 73428 | |
| Kreiskliniken Esslingen gGmbH, Klinik Nürtingen, Medizinische Klinik I | |
| Nürtingen, Baden-Württemberg, Germany, 72622 | |
| Gemeinschaftspraxis Onkologie Ravensburg | |
| Ravensburg, Baden-Württemberg, Germany, 88214 | |
| Gemeinschaftspraxis Dr. med. U. Banhardt, Dr. med. T. Fietz | |
| Singen, Baden-Württemberg, Germany, 78224 | |
| Universitätsklinikum Ulm, Zentrum für Innere Medizin, Klinik für Innere Medizin I | |
| Ulm, Baden-Württemberg, Germany, 89070 | |
| Überörtliche Gemeinschaftspraxis Dres. Wilke und Wagner | |
| Fürth, Bayern, Germany, 90766 | |
| Hämatologischonkologische Schwerpunktpraxis | |
| Herrsching, Bayern, Germany, 82211 | |
| Hämatologie Onkologie Tagesklinik Landshut | |
| Landshut, Bayern, Germany, 84028 | |
| Hämato-Onkologische Schwerpunktpraxis Prof. Salat / Dr. Stoetzer / Prof. Hiller | |
| München, Bayern, Germany, 80639 | |
| Leopoldina-Krankenhaus, Medizinische Klinik II | |
| Schweinfurt, Bayern, Germany, 97422 | |
| Kreiskliniken Traunstein -Trostberg GmbH , Innere Medizin/ Hämatologie und Onkologie | |
| Trostberg, Bayern, Germany, 83308 | |
| Klinikum Darmstadt, Medizinische Klinik V | |
| Darmstadt, Hessen, Germany, 64283 | |
| Städtische Kliniken Frankfurt a.M. - Höchst, Klinik für Innere Medizin Abt. 3 | |
| Frankfurt a.M., Hessen, Germany, 65929 | |
| Vitanus GmbH | |
| Frankfurt, Hessen, Germany, 60596 | |
| Klinikum Fulda, Tumorklinik | |
| Fulda, Hessen, Germany, 36043 | |
| Onkologische Praxisgemeinschaft Dres. Siehl, Söling und Prof. Hirschmann | |
| Kassel, Hessen, Germany, 34117 | |
| Philipps-Universität, Klinikum Marburg, Klinik für Innere Medizin mit SP Hämatologie und Onkologie | |
| Marburg, Hessen, Germany, 35043 | |
| Gemeinschaftspraxis für Hämatologie und Internistische Onkologie | |
| Offenbach, Hessen, Germany, 63065 | |
| Lahn-Dill-Kliniken GmbH, Darmzentrum | |
| Wetzlar, Hessen, Germany, 35578 | |
| Universitätsklinikum Rostock, Klinik für Innere Medizin | |
| Rostock, Mecklenburg-Vorpommern, Germany, 18057 | |
| Wissenschaftskontor Nord GmbH und Co KG | |
| Rostock, Mecklenburg-Vorpommern, Germany, 18107 | |
| MediProjekt, Gesellschaft für Medizinstatistik und Projektentwicklung | |
| Hannover, Niedersachsen, Germany, 30171 | |
| Krankenhaus Siloah, Medizinische Klinik III | |
| Hannover, Niedersachsen, Germany, 30449 | |
| Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Endokrinologie | |
| Hannover, Niedersachsen, Germany, 30625 | |
| Onkologische Schwerpunktpraxis Hildesheim | |
| Hildesheim, Niedersachsen, Germany, 31135 | |
| Hämatologie u. Internistische Onkologie | |
| Lehrte, Niedersachsen, Germany, 31275 | |
| Hämatologisch-onkologische Schwerpunktpraxis Northeim | |
| Northeim, Niedersachsen, Germany, 37154 | |
| Niels-Stensen-Kliniken, Marienhospital Osnabrück GmbH, | |
| Osnabrück, Niedersachsen, Germany, 49074 | |
| Diakoniekrankenhaus Rotenburg (Wümme) gGmbH, I. Chirurgische Klinik | |
| Rotenburg (Wümme), Niedersachsen, Germany, 27356 | |
| Praxisgemeinschaft Dr. Hancken und Partner, Onkologische Schwerpunktpraxis | |
| Stade, Niedersachsen, Germany, 21680 | |
| Medizinische Universitätsklinik-Knappschaftskrankenhaus, Medizinische Klinik | |
| Bochum, Nordrhein-Westfalen, Germany, 44892 | |
| St. Vincenz-Krankenhaus, Medizinische Klinik I | |
| Datteln, Nordrhein-Westfalen, Germany, 45711 | |
| St. Antonius Hospital, Klinik für Hämatologie / Onkologie | |
| Eschweiler, Nordrhein-Westfalen, Germany, 52249 | |
| Hämato-Onkologisches Gemeinschaftspraxis | |
| Essen, Nordrhein-Westfalen, Germany, 45136 | |
| Katholisches Krankenhaus Hagen gem. GmbH, Klinik für Hämatologie und Onkologie | |
| Hagen, Nordrhein-Westfalen, Germany, 58095 | |
| Gemeinschaftspraxis für Hämatologie und Onkologie am Sachsenring | |
| Köln, Nordrhein-Westfalen, Germany, 50677 | |
| Klinikum Leverkusen gGmbH, Medizinische Klinik III | |
| Leverkusen, Nordrhein-Westfalen, Germany, 51375 | |
| Gemeinschaftspraxis Hämatologie und Onkologie | |
| Münster, Nordrhein-Westfalen, Germany, 48149 | |
| Praxis und Tagesklinik für Internistische Onkologie und Hämatologie | |
| Recklinghausen, Nordrhein-Westfalen, Germany, 45657 | |
| Prosperhospital Recklinghausen, Medizinische Klinik I | |
| Recklinghausen, Nordrhein-Westfalen, Germany, 45659 | |
| Internistische Gemeinschaftspraxis | |
| Witten, Nordrhein-Westfalen, Germany, 58452 | |
| HELIOS Klinikum Wuppertal , Medizinische Klinik I | |
| Wuppertal, Nordrhein-Westfalen, Germany, 42283 | |
| I. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz | |
| Mainz, Rheinland-Pfalz, Germany, 55131 | |
| Klinikum Mutterhaus der Borromäerinnen gGmbH, Innere Medizin I | |
| Trier, Rheinland-Pfalz, Germany, 54290 | |
| Universitätskliniken des Saarlandes, Innere Medizin I | |
| Homburg / Saar, Saarland, Germany, 66421 | |
| Hämatologisch-onkologische Praxis Dr. med. Peter Schmidt | |
| Neunkirchen, Saarland, Germany, 66821 | |
| Städtisches Klinikum Dessau, Klinik für Innere Medizin | |
| Dessau, Sachsen-Anhalt, Germany, 06847 | |
| Onkologische Gemeinschaftspraxis | |
| Halle (Saale), Sachsen-Anhalt, Germany, 06110 | |
| Gemeinschaftspraxis für Hämatologie und Internistische Onkologie | |
| Magdeburg, Sachsen-Anhalt, Germany, 39104 | |
| Praxisgemeinschaft Dr. med. Thomas Göhler und Steffen Dörfel | |
| Dresden, Sachsen, Germany, 01127 | |
| Internistische Praxis & Tagesklinik | |
| Neutstadt/Sachsen, Sachsen, Germany, 01844 | |
| Friedrich-Ebert-Krankenhaus Neumünster, Klinik für Hämatologie, Onkologie und Nephrologie | |
| Neumünster, Schleswig-Holstein, Germany, 24534 | |
| eps-early phase solution GmbH | |
| Jena, Thüringen, Germany, 07743 | |
| Sophien- und Hufeland-Klinikum gGmbH, Klinik für Innere Medizin II | |
| Weimar, Thüringen, Germany, 99425 | |
| DIAKO Ev. Diakonie-Krankenhaus gGmbH, Medizinische Klinik II | |
| Bremen, Germany, 28239 | |
| MVZ für Innere Medizin in Hamburg Eppendorf | |
| Hamburg, Germany, 20248 | |
Sponsors and Collaborators
AIO-Studien-gGmbH
Investigators
| Principal Investigator: | Thomas Höhler, Prof. Dr. med. |
Additional Information:
| Responsible Party: | AIO-Studien-gGmbH |
| ClinicalTrials.gov Identifier: | NCT00889343 History of Changes |
| Other Study ID Numbers: |
AIO KRK 0307 |
| First Posted: | April 28, 2009 Key Record Dates |
| Last Update Posted: | March 4, 2013 |
| Last Verified: | March 2013 |
Keywords provided by AIO-Studien-gGmbH:
|
Second-line therapy of metastatic colorectal cancer Sorafenib Colorectal Neoplasms palliative therapy after progression of firstline therapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Oxaliplatin Irinotecan Sorafenib Fluorouracil |
Niacinamide Antineoplastic Agents Antineoplastic Agents, Phytogenic Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antimetabolites Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Protein Kinase Inhibitors Vitamin B Complex Vitamins |